Zymeworks has positive Phase 1 cancer data at ASCO

Zymeworks announced the presentation of ZW25 clinical data by Funda Meric-Bernstam, MD, Principal Investigator for the ZW25 study at the University of Texas MD Anderson Cancer Center. Data from the ongoing multi-center Phase 1 study showed single agent ZW25 induced anti-tumor activity and was well tolerated in heavily pretreated patients across a range of HER2-expressing cancers. “Since the first patient treated, ZW25’s compelling single agent activity has consistently exceeded our expectations,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks. “The expanded body of data presented today supports our confidence that ZW25 is an active agent with the potential to become an approved cancer treatment.”

https://bit.ly/2syCazS